

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No. 91120000103100784F)

(Incorporated in People's Republic of China)

Resolutions Passed at the 7th Supervisory Committee Meeting for FY2019

The board of directors (the "Board") and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The 7th supervisory committee (the "**Supervisory Committee**") meeting of the Company was duly convened on 29 October 2019.

The said meeting was convened in compliance with the Articles of Association of the Company, and the following resolutions were discussed and passed by 3 members out of the full Supervisory Committee of 3 members:

1. That, the third quarter financial statement for financial year ending 31 December 2019 ("**FY2019**") of the Company be approved.

The Supervisory Committee is of view that:

- (a) the preparation and review procedures of the third quarter financial statement for FY2019 of the Company are in compliance with the provisions of laws, regulations, the Articles of Associations and the internal management policies of the Company;
 - (b) the content and format of the third quarter financial statement for FY2019 of the Company are in compliance with the provisions of the China Securities Regulatory Commission and the stock exchange, and the information contained therein truly reflects the Company's business management and financial status for the current financial period from all aspects; and
 - (c) no violation of confidentiality provisions were found among those involved in the preparation and review of the third quarter financial statement for FY2019 of the Company prior to the issue of the opinions herein.
2. That, due to the job assignment change of Mr. Zhang Bingqiang, the resignation of Mr. Zhang Bingqiang as Chairman of the Supervisory Committee and as a member of the Supervisory Committee be approved, and his resignation shall take effect from the date of the appointment of the new member of the Supervisory Committee at a general meeting of the Company.
 3. That, the appointment of Mr. Wang Yuanxi as a member of the Supervisory Committee be approved.

Mr. Wang Yuanxi, born in January 1978, is an economist. Mr. Wang obtained his bachelor degree of chemical engineering from Tianjin University of Science and Technology and his MBA from Tianjin University. From July 2002 to September 2008, he successively served

as a staff of Tianjin Tianyao Pharmaceutical Co., Ltd., Tianjin Jinyao Group Co., Ltd. and Tianjin Pharmaceutical Group Co., Ltd. From September 2008 to December 2013, he successively held the positions as Deputy Director of the Board of Director Office and the President Office of Tianjin Jinyao Group Co., Ltd., and Deputy Director of the Board of Director Office and the Manager Office of Tianjin Pharmaceutical Group Co., Ltd. Mr. Wang was appointed as Deputy Director, and then was promoted as Director, of the General Manager Office of Tianjin Pharmaceutical Holdings Co., Ltd. for the period from December 2013 to August 2019. He was appointed as a Director of Tianjin Pharmaceutical Group International Holdings Co., Ltd. since October 2017, Party Branch Secretary and Executive Director of Tianjin Pharmaceutical Group Sales Co., Ltd. since May 2018 and Director of the Party Committee Office and Director of the Board of Director Office of Tianjin Pharmaceutical Holdings Co., Ltd. since August 2019.

The above resolution No.3 shall be tabled for shareholders' approval, at a general meeting of the Company to be convened in due course.

By order of the Board
30 October 2019